MN
Monopar Therapeutics Inc.
MNPR · NASDAQ
$96.47 -7.20% (-$7.49)
1M -13.37%
Market Cap $688.0M
P/E Ratio -
Div. Yield -
ROE 13.08%
Bulios Fair Price
$48.34
49.9% downside
Current Price
$96.47
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MNPR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
0/9Valuation
34 /100
Fair P/B 5.26x
P/FCF N/A
P/FFO N/A
Growth
100 /100
Growing Book val. growth 139.05%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 13.22%
ROIC 16.89%
Debt
100 /100
Low Current ratio 33.56x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
13 /100
Unstable EPS volatility 82.83%
Profitable years 0
Beta 1.50x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MNPR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chandler D. Robinson
Employees
22
Headquarters
Wilmette
Upcoming events
12 NOV
Earnings
Upcoming earnings report